Gatifloxacin

• CAT Number: A000459
• CAS Number: 112811-59-3
• Molecular Formula: C19H22FN3O4
• Molecular Weight: 375.4
• Purity: ≥95%
• Target: Topoisomerase
• Solubility: Limited solubility
• Storage: -20°C
• InChI: 1S/C19H22FN3O4/c1-10-8-22(6-5-21-10)16-14(20)7-12-15(18(16)27-2)23(11-3-4-11)9-13(17(12)24)19(25)26/h7,9-11,21H,3-6,8H2,1-2H3,(H,25,26)
• InChIKey: XUBOMFCQGDBHNK-UHFFFAOYSA-N
• SMILES: CC1CN(CCN1)C2=C(C=C3C(=C2OC)N(C=C(C3=O)C(=O)O)C4CC4)F

Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family that inhibits the bacterial enzymes DNA gyrase and topoisomerase IV. Gatifloxacin is a fluoroquinolone antibiotic, with potent activity against Gram-negative and Gram-positive bacteria. Bristol-Myers Squibb introduced Gatifloxacin in 1999 under the proprietary name Tequin for the treatment of respiratory tract infections. Allergan produces it in eye-drop formulation under the names Zymar and Zymaxid. In many countries, gatifloxacin is also available as tablets and in various aqueous solutions for intravenous therapy.

Reference

1: Dawn A, Chandra H, Ade-Browne C, Yadav J, Kumari H. Multifaceted
Supramolecular Interactions from C-methylresorcin[4]arene Lead to an Enhancement
in In Vitro Antibacterial Activity of Gatifloxacin. Chemistry. 2017 Oct 12. doi:
10.1002/chem.201704291. [Epub ahead of print] PubMed PMID: 29027275.

2: Pienaar E, Sarathy J, Prideaux B, Dietzold J, Dartois V, Kirschner DE,
Linderman JJ. Comparing efficacies of moxifloxacin, levofloxacin and gatifloxacin
in tuberculosis granulomas using a multi-scale systems pharmacology approach.
PLoS Comput Biol. 2017 Aug 17;13(8):e1005650. doi: 10.1371/journal.pcbi.1005650.
eCollection 2017 Aug. PubMed PMID: 28817561; PubMed Central PMCID: PMC5560534.

3: Pang Y, Zong Z, Huo F, Jing W, Ma Y, Dong L, Li Y, Zhao L, Fu Y, Huang H. In
Vitro Drug Susceptibility of Bedaquiline, Delamanid, Linezolid, Clofazimine,
Moxifloxacin, and Gatifloxacin against Extensively Drug-Resistant Tuberculosis in
Beijing, China. Antimicrob Agents Chemother. 2017 Sep 22;61(10). pii: e00900-17.
doi: 10.1128/AAC.00900-17. Print 2017 Oct. PubMed PMID: 28739779; PubMed Central
PMCID: PMC5610515.

4: Xu Z, Zhang S, Song X, Qiang M, Lv Z. Design, synthesis and in vitro
anti-mycobacterial evaluation of gatifloxacin-1H-1,2,3-triazole-isatin hybrids.
Bioorg Med Chem Lett. 2017 Aug 15;27(16):3643-3646. doi:
10.1016/j.bmcl.2017.07.023. Epub 2017 Jul 8. PubMed PMID: 28720502.

5: Xu Z, Song XF, Hu YQ, Qiang M, Lv ZS. Azide-alkyne cycloaddition towards
1H-1,2,3-triazole-tethered gatifloxacin and isatin conjugates: Design, synthesis
and in vitro anti-mycobacterial evaluation. Eur J Med Chem. 2017 Sep
29;138:66-71. doi: 10.1016/j.ejmech.2017.05.057. Epub 2017 Jun 9. PubMed PMID:
28646656.

6: Olliaro PL, Merle C, Mthiyane T, Bah B, Kassa F, Amukoye E, N Diaye A,
Perronne C, Lienhardt C, McIlleron H, Fielding K. Effects on the QT Interval of a
Gatifloxacin-Containing Regimen versus Standard Treatment of Pulmonary
Tuberculosis. Antimicrob Agents Chemother. 2017 Jun 27;61(7). pii: e01834-16.
doi: 10.1128/AAC.01834-16. Print 2017 Jul. PubMed PMID: 28438924; PubMed Central
PMCID: PMC5487672.

7: Marcianes P, Negro S, García-García L, Montejo C, Barcia E,
Fernández-Carballido A. Surface-modified gatifloxacin nanoparticles with
potential for treating central nervous system tuberculosis. Int J Nanomedicine.
2017 Mar 13;12:1959-1968. doi: 10.2147/IJN.S130908. eCollection 2017. PubMed
PMID: 28331318; PubMed Central PMCID: PMC5357078.

8: Sanfilippo CM, Allaire CM, DeCory HH. Besifloxacin Ophthalmic Suspension 0.6%
Compared with Gatifloxacin Ophthalmic Solution 0.3% for the Treatment of
Bacterial Conjunctivitis in Neonates. Drugs R D. 2017 Mar;17(1):167-175. doi:
10.1007/s40268-016-0164-6. PubMed PMID: 28078599; PubMed Central PMCID:
PMC5318332.

9: Kozai S, Wada T, Ogawara KI, Kida T, Tokushige H, Higaki K. Evaluation of
pharmacokinetic/pharmacodynamic indices of topical ophthalmic gatifloxacin
against Staphylococcus aureus utilising an in vitro aqueous humour
pharmacokinetic model. Int J Antimicrob Agents. 2017 Jan;49(1):113-115. doi:
10.1016/j.ijantimicag.2016.10.004. Epub 2016 Oct 24. PubMed PMID: 27817974.

10: Domingos LC, Moreira MV, Keller KM, Viana FA, Melo MM, Soto-Blanco B.
Simultaneous quantification of gatifloxacin, moxifloxacin, and besifloxacin
concentrations in cornea and aqueous humor by LC-QTOF/MS after topical ocular
dosing. J Pharmacol Toxicol Methods. 2017 Jan – Feb;83:87-93. doi:
10.1016/j.vascn.2016.09.006. Epub 2016 Sep 23. PubMed PMID: 27670369.